Mounjaro generic
Mounjaro is an anti-diabetic drug that is manufactured by Eli Lilly And Co. It contains the active ingredient tirzepatide and was first authorized for market use on 13 May, 2022. Mounjaro has a total of 4 patents with none of them having expired as yet. It's available in solution form and administered subcutaneously.
When will Mounjaro generic be available?
The Mounjaro generic is likely to be made available after 14 June, 2039. This is due to existing patents that Eli Lilly And Co. holds on the drug. The last patent, 'GIP/GLP1 agonist compositions' (US11357820), is set to expire on 2039-06-14. Nonetheless, patent challenges against Mounjaro can be filed from 2026-05-13, potentially paving the way for an earlier release of the generic version.
Mounjaro uses
Mounjaro is primarily used to improve glycemic control in adults suffering from type 2 diabetes mellitus. It works as an adjunct to diet and exercise. The active ingredient, tirzepatide, helps regulate blood sugar levels effectively, making this drug a reliable choice for managing diabetes.
Mounjaro patent expiration
Mounjaro holds four patents, the last of which is set to expire on 14 June, 2039 (US patent number US11357820), protecting its exclusivity status. Because of these patents, the Mounjaro generic isn't expected to be on the market until post-June 2039 at the earliest. Below is the detail of the patent: